A Protocol for the Role of Fractional CO2 Laser in Consolidation Treatment of Recurrent Vulvovaginal Candidiasis
NCT04292704 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 205
Last updated 2020-03-11
Summary
Background: Recurrent vulvovaginal candidiasis (RVVC) is a common obstinate vulvovaginal inflammation in gynecology. At present, the pathogenesis of RVVC is not clear. In recent years, it is emphasized that the changes of vaginal microecological environment play an important role in the occurrence and development of RVVC. The treatment of RVVC can be divided into intensive treatment and consolidation treatment. Currently, local antifungal treatment is the main treatment regimen. While it is difficult and had an insufficient effect on prevention from recurrence of clinical signs and the improvement of vaginal mycological status in long term. Besides, there is no mature consolidation treatment regimen at home and abroad. Through the current application of the fractional CO2 laser in the treatment of atrophic vaginitis, it is confirmed that local irradiation of the fractional CO2 laser on vulva and vagina can regenerate and repair mucosal tissue, enhance the function of vaginal epithelial cells, gradually restore the normal pH value of vagina, improve vaginal microecological environment, restore the proportion of vaginal flora and reduce the recurrence rate of RVVC. This trial aims to explore the efficacy of two consolidation therapy schemes: the fractional CO2 laser and traditional antifungal drugs.
Methods/Design: The ongoing study will include 200 RVVC patients who voluntarily joined the study and signed the informed consent form the Second Affiliated Hospital of WMU during December 2019 to March 2022. After patients were cured by transvaginal local drug intensive therapy, participants will be randomly divided into control group (n = 100) and experimental group (n = 100). The control group continue to receive a monthly course of vaginal local drug consolidation therapy for 6 months, while the experimental group will be given monthly local vaginal CO2 laser consolidation therapy for 3 months. The vaginal secretions samples of RVVC patients will be collected before intensive therapy, after intensive therapy and at the end of consolidation therapy, and the species abundance and structure of vaginal flora were detected and analyzed. In the same period, 5 healthy women of childbearing age were recruited as the normal control group and the volunteers do not take any treatment. The vaginal secretions samples of 5 volunteers will be collected when signing the informed consent to detect and analyze the species abundance and structure of vaginal flora.
The patients with RVVC will be followed up for 3, 6 and 12 months after the treatment and vaginal secretions samples will be collected for vaginal flora structure detection to compare the vaginal microecological environment. For recurrent patients, the investigators will carry out targeted treatment, and again collect vaginal secretions sample to detect and analyze the species abundance and structure of vaginal flora.
Objectives: The aim of this study is to compare the effects of fractional CO2 laser consolidation therapy and traditional antifungal consolidation therapy for RVVC, and assess the role of fractional CO2 laser in changes of vaginal microecological environment and recurrence rate of VVC after consolidation treatment.
Conditions
- Vulvovaginal Candidiasis, Genital
- Laser Therapy
Interventions
- RADIATION
-
the fractional CO2 laser
The fractional CO2 laser therapy mechine: the wavelength is 10.6 μ m, the output power is 40 w, the action time is 2000 μ s and the lattice spacing is 700 \~ 1000 μ m
- DRUG
-
Clotrimazole
Clotrimazole vaginal tablets
Sponsors & Collaborators
-
Shanghai Pudong Decoding Life Institutes
collaborator UNKNOWN -
Second Affiliated Hospital of Wenzhou Medical University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 60 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2019-12-13
- Primary Completion
- 2022-03-31
- Completion
- 2022-05-31
Countries
- China
Study Locations
More Related Trials
-
Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)
NCT04029116 ·Status: COMPLETED ·Phase: PHASE3
-
Vulvovaginal Candidiasis in Canadian Females
NCT04930107 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis
NCT05074602 ·Status: UNKNOWN ·Phase: PHASE3
-
The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis
NCT05235711 ·Status: COMPLETED
-
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
NCT02180828 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Different Doses of Venus Association in Patients With Vulvovaginal Candidiasis.
NCT05031481 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
NCT02267382 ·Status: COMPLETED ·Phase: PHASE2
-
Epidemiological Study of Vulvovaginal Candidiases Strain Types and Risk Factors Among Gynecological Outpatients in China
NCT06200389 ·Status: NOT_YET_RECRUITING
-
Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
NCT02242695 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Boric Acid vs. Terconazole in Treatment of RVVC
NCT04208555 ·Status: UNKNOWN ·Phase: NA
-
A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
NCT03561701 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge
NCT02111629 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole
NCT05178862 ·Status: TERMINATED ·Phase: PHASE3
-
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
NCT00037219 ·Status: COMPLETED ·Phase: PHASE2
-
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
NCT05399641 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Voriconazole Loaded Spanlastics Gel Versus Clotriamazole Cream on Treating Vulvovaginal Candidasis
NCT06392529 ·Status: COMPLETED
-
RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections
NCT02733432 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Oral Ibrexafungerp (SCY-078) vs. Placebo in Subjects With Acute Vulvovaginal Candidiasis
NCT03987620 ·Status: COMPLETED ·Phase: PHASE3
-
CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension
NCT02734862 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
NCT01092832 ·Status: TERMINATED ·Phase: PHASE3
-
Isavuconazole in Critically Ill Patients: Efficacy and Safety
NCT07080359 ·Status: NOT_YET_RECRUITING
-
A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
NCT03562156 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Oral Encochleated Amphotericin B (CAMB/MAT2203) in the Treatment of Vulvovaginal Candidiasis (VVC)
NCT02971007 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis
NCT03253094 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Antibiotic-induced Vaginal Yeast Infections in Healthy Women
NCT01915251 ·Status: TERMINATED